JTC Team to Host Virtual Investor Innovation in Oncology Featuring Xenetic Biosciences
JTC Team to Host Virtual Investor Innovation in Oncology Featuring Xenetic Biosciences
- Live video webcast with moderated roundtable with members of the Xenetic leadership team and surgical oncology Key Opinion Leader, Allan Tsung, MD on Thursday, June 9th at 11:00 AM ET -
-現場視頻網絡直播，與Xenetic領導團隊成員和外科腫瘤學關鍵意見領袖Allan Tung，MD於6月9日星期四上午11：00舉行圓桌會議-
FRENCHTOWN, NJ / ACCESSWIRE / June 2, 2022 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor Innovation in Oncology Event Featuring Xenetic Biosciences on Thursday, June 9, 2022 at 11:00 AM ET. Access the event here.
新澤西州弗倫奇敦/ACCESSWIRE/2022年6月2日 / JTC Team(“JTC”)，一家完全集成的企業溝通和投資者關係公司，今天宣佈，它將於2022年6月9日(星期四)美國東部時間上午11：00主辦以Xenetic Biosciences為特色的虛擬投資者腫瘤學創新活動。點擊此處訪問該活動。
Xenetic Biosciences, Inc. (NASDAQ:XBIO) is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications. The Company's DNase oncology platform, in development for the treatment of solid tumors, is aimed at improving outcomes of existing treatments, including immunotherapies, by targeting Neutrophil Extracellular Traps (NETs). The Company is also developing its personalized CAR T platform technology, XCARTT, to develop cell-based therapeutics targeting the unique B-Cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-Cell lymphomas.
Xenetic Biosciences，Inc.(納斯達克代碼：XBIO)是一家生物製藥公司，專注於推進創新的免疫腫瘤技術，解決難以治療的腫瘤適應症。該公司的DNase腫瘤學平臺正在開發中，用於治療實體腫瘤，旨在通過瞄準中性粒細胞細胞外陷阱(Net)來改善現有治療方法的結果，包括免疫療法。該公司還在開發其個性化CAR T平臺技術XCARTT，以開發針對單個患者惡性腫瘤細胞表面獨特的B細胞受體的基於細胞的療法，用於治療B細胞淋巴瘤。
For the roundtable discussion, Jeffrey F. Eisenberg, Chief Executive Officer and Curtis A. Lockshin, PhD, Chief Scientific Officer of Xenetic Biosciences will be joined by Allan Tsung, MD, Scientific Advisor to the Company, Director of Surgical Oncology at the Ohio State James Comprehensive Cancer Center and Co-Director of the Gastrointestinal Clinical Trials portfolio, and recently appointed Chair of the Department of Surgery at the University of Virginia School of Medicine and Director of the Cancer Therapeutics program at the UVA Comprehensive Cancer Center.
在圓桌會議上，基因生物科學部首席執行官兼首席科學官Jeffrey F.Eisenberg博士將與公司的科學顧問Allan Tung醫學博士、俄亥俄州立大學詹姆斯綜合癌症中心外科腫瘤科的董事主任、胃腸道臨牀試驗組合的聯合董事專家、以及最近被任命為弗吉尼亞大學醫學院外科系主任以及弗吉尼亞大學癌症綜合中心癌症治療計劃的董事主任一起參加圓桌會議。
In addition to the moderated portion of the event, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible during the event.
除了活動的緩和部分，投資者和感興趣的各方將有機會在活動期間現場提交問題。公司將在活動期間回答儘可能多的問題。
A live video webcast of the Virtual Investor Innovation in Oncology Event Featuring Xenetic Biosciences will be available on virtualinvestorco.com. A webcast replay will be made available shortly after the conclusion of the live event and will be accessible for 90 days.
以Xenetic Biosciences為特色的虛擬投資者腫瘤學創新活動的現場視頻網絡直播將在VirtualInvest orco.com上播出。直播活動結束後不久將提供網絡直播重播，並將在90天內提供重播。
About JTC Team
關於JTC團隊
JTC is a fully integrated corporate communications firm that is dedicated to helping you tell your story to the right audiences in order to build awareness. JTC has developed a reputation of excellence for executing on robust communication strategies that deliver results. The Company partners with both public and private companies across the Life Sciences and Technology industries to help raise awareness and build stakeholder value. For more information, please visit or connect with the company on Twitter and LinkedIn.
JTC是一家完全集成的企業傳播公司，致力於幫助您向合適的受眾講述您的故事，以便建立知名度。JTC建立了卓越的聲譽，因為它執行穩健的溝通戰略，交付成果。該公司與生命科學和技術行業的公共和私營公司合作，幫助提高認識和建立利益相關者價值。欲瞭解更多信息，請訪問該公司或在Twitter和LinkedIn上與其聯繫。
Contact:
聯繫方式：
Jenene Thomas
珍妮·託馬斯
JTC Team, LLC
JTC團隊，有限責任公司
T: +1 (833) 475-8247
T: +1 (833) 475-8247
jtc@jtcir.com
郵箱：jtc@jtCir.com
SOURCE: JTC Team, LLC
資料來源：JTC團隊，有限責任公司
View source version on accesswire.com:
在accesswire.com上查看源代碼版本：
COMTEX_408110882/2457/2022-06-02T14:00:49
COMETX_408110882/2457/2022-06-02T14：00：49